Book a demo
Skip to content

Stonewake Monitoring

TuHURA Biosciences files 8-K reporting a debt obligation

The Nasdaq-listed pharmaceutical company filed an 8-K dated September 17, 2026, a day after an executive departure was recorded.

Export financeUSAPublished · 3 sourced facts

TuHURA Biosciences, Inc./NV, a Nevada-incorporated pharmaceutical preparations company traded on Nasdaq under the ticker HURA, filed an 8-K on September 17, 2026.[1][2]

The filing carries the accession number 0001193125-26-394473, includes items 2.03 and 9.01, and is described as a debt obligation filing.[1]

The filing's primary document is hura-20260914.htm and covers a period ending September 14, 2026.[1]

The company separately recorded an executive departure on September 16, 2026, one day before the filing.[3]

Sources

  1. [1]SEC EDGAR: 8-K, 0001193125-26-394473, 17 Sep 2026
  2. [2]SEC EDGAR: CIK 0001498382, TuHURA Biosciences, Inc./NV
  3. [3]SEC EDGAR

SEC EDGAR

← All briefs